Therapy of visceral leishmaniasis in renal transplant recipients intolerant to pentavalent antimonials.
Visceral leishmaniasis should be suspected in renal transplant recipients in whom a fever develops of unknown origin. A 53-year-old renal transplant recipient developed pyrexia, hepatosplenomegaly, and pancytopenia 4 years after transplantation. Antileishmaniasis serology was negative, and the diagnosis was confirmed through bone marrow examination. Treatment with glucantine (N-methylglucamine antimoniate) led to acute pancreatitis, and treatment with ketoconazole plus allopurinol for 21 days was effective to eradicate Leishmania donovani.
Llorente
S
S
Nephrology Service, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
Gimeno
L
L
Navarro
M J
MJ
Moreno
S
S
Rodriguez-Gironés
M
M
D000965:Antimony / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects*; D007898:Leishmaniasis, Visceral / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use
D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D000965:Antimony